{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"31.0","value":"19.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Response \\[complete response (CR), partial response (PR), and stable disease (SD)\\] was assessed after approximately 2 months, 6 months and then every 4 months, until progression of disease. Response and progression of disease evaluation is based on the criteria reported by Blade, et al. (1998).","dispersionType":"Full Range","groups":[{"description":"TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.","id":"OG000","title":"Sea Cucumber Extract (TBL 12)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Duration of Response (All Treated Patients)","type":"PRIMARY","unitOfMeasure":"months"}